GALT Galectin Therapeutics Inc

Price (delayed)

$2.375

Market cap

$156.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$278.01M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a ...

Highlights
Galectin Therapeutics's EPS has increased by 43% YoY and by 15% QoQ
The company's net income rose by 42% YoY and by 15% QoQ
The debt has grown by 26% YoY
GALT's equity is down by 16% year-on-year and by 3.2% since the previous quarter

Key stats

What are the main financial stats of GALT

GALT stock price

How has the Galectin Therapeutics stock price performed over time
Intraday
1.06%
1 week
-7.59%
1 month
3.71%
1 year
85.55%
YTD
-42.91%
QTD
-14.87%

Financial performance

How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.27M
Net income
-$26.25M
Gross margin
N/A
Net margin
N/A
The operating income has surged by 60% year-on-year and by 19% since the previous quarter
The company's net income rose by 42% YoY and by 15% QoQ

Price vs fundamentals

How does GALT's price correlate with its fundamentals

Growth

What is Galectin Therapeutics's growth rate over time

Valuation

What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has increased by 43% YoY and by 15% QoQ
GALT's equity is down by 16% year-on-year and by 3.2% since the previous quarter

Efficiency

How efficient is Galectin Therapeutics business performance
GALT's ROIC has soared by 68% YoY and by 50% QoQ
The ROA has grown by 23% YoY and by 23% from the previous quarter

Dividends

What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GALT.

Financial health

How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 89% less than its total liabilities
Galectin Therapeutics's total assets has soared by 65% YoY but it has decreased by 19% from the previous quarter
The total liabilities has grown by 20% YoY
The debt has grown by 26% YoY
GALT's equity is down by 16% year-on-year and by 3.2% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.